Our Approach

CURE-SHOCK uses a multifaceted, interdisciplinary approach to evaluate Invobenitug as a targeted treatment for shock. By applying a precision medicine approach within an international clinical trial, the consortium aims to improve patient care and generate new insights into the treatment of severe shock.

Clinical Trial

At the heart of CURE-SHOCK is a multicentre trial involving patients with septic, burn and traumatic shock at four expert centres in Germany, Poland and Ukraine. The study will investigate whether treatment with Invobenitug can improve patient outcomes.

1. DPP3-Based Patient Selection: A key element of the CURE-SHOCK trial is its precision medicine strategy. Participants are first tested for elevated levels of the enzyme DPP3 using a rapid bedside test, helping to identify patients who may benefit most from treatment.

2. Targeted Treatment: Patients with high DPP3 levels receive Invobenitug, in addition to standard care. The novel antibody is specifically designed to neutralise excessive DPP3 activity in the bloodstream, aiming to restore circulatory stability and reducing the risk of organ failure.

3. Clinical Evaluation: Throughout the trial, researchers closely monitor patient safety and treatment response. Treatment efficacy is assessed by the number of days without cardiovascular or circulatory support within the first 30 days, while safety is assessed by monitoring side effects, serious complications and treatment-related deaths.